Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BioGaia AB ( ($SE:BIOG.B) ) has issued an update.
BioGaia AB reported a modest increase in net sales for the first half of 2025, with significant growth in the Adult Health segment. However, operating profit and profit after tax both saw declines, attributed to increased operating expenses. The company is expanding its global presence with direct sales in the Netherlands and has launched a new subsidiary, BioGaia New Sciences AB, to advance microbiome research.
More about BioGaia AB
BioGaia AB is a company operating in the probiotics industry, focusing on the development and sale of probiotic products aimed at improving health. The company primarily targets the Pediatrics and Adult Health segments, with a market focus on expanding its global footprint.
Average Trading Volume: 201,627
Current Market Cap: SEK10.97B
For an in-depth examination of BIOG.B stock, go to TipRanks’ Overview page.